Pfizer Names LaMattina To Head R&D; Licensing Is “Corr” Function
Executive Summary
Pfizer Global R&D President John LaMattina, PhD, will attempt to enhance the productivity of the largest pharmaceutical research operation in the world
You may also be interested in...
Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent
Pfizer's newly created corporate executive committee streamlines the company's top management structure
Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent
Pfizer's newly created corporate executive committee streamlines the company's top management structure
Vertex board adds former HHS official
Vertex will nominate former HHS Assistant Secretary for Health Eve Slater, MD, to board of directors at annual meeting May 6. Slater served at HHS for a year after a 19-year career at Merck. She left HHS in February 2003 (1"The Pink Sheet" July 28, 2003, In Brief). Vertex also plans to nominate former Pfizer President-Global R&D John Niblack, PhD, to board. Niblack retired from Pfizer in 2002 (2"The Pink Sheet" Oct. 27, 2003, p. 20)...